Coloplast reported estimate-beating Q4 21 numbers, with sales up 10% on an organic basis. However, the beat was overshadowed by a soft FY 22 outlook (7% growth vs 7-9% long-term outlook), which was attributable to the COVID-19 uncertainty, especially in the US and China. Given the soft outlook, we will be downgrading our estimates marginally.
02 Nov 2021
FY 22 guidance plays spoilsport
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY 22 guidance plays spoilsport
- Published:
02 Nov 2021 -
Author:
Virendra Chauhan -
Pages:
3
Coloplast reported estimate-beating Q4 21 numbers, with sales up 10% on an organic basis. However, the beat was overshadowed by a soft FY 22 outlook (7% growth vs 7-9% long-term outlook), which was attributable to the COVID-19 uncertainty, especially in the US and China. Given the soft outlook, we will be downgrading our estimates marginally.